Health Care & Life Sciences » Pharmaceuticals | Adamas Pharmaceuticals Inc.

Adamas Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
71,095.00
55,846.00
1,916.00
572.00
571.00
34,046
Cost of Goods Sold (COGS) incl. D&A
-
-
-
-
1,211.00
2,093
Gross Income
-
-
-
-
640.00
31,953
SG&A Expense
14,011.00
37,177.00
58,918.00
63,148.00
87,319.00
146,976
EBIT
57,018.00
18,514.00
57,437.00
63,384.00
87,959.00
115,023
Unusual Expense
4,526.00
983.00
-
2,400.00
33.00
881
Non Operating Income/Expense
292.00
66.00
363.00
811.00
1,351.00
3,997
Interest Expense
88.00
-
-
-
4,645.00
19,092
Pretax Income
52,112.00
17,597.00
57,074.00
60,173.00
91,220.00
130,999
Income Tax
1,191.00
7,374.00
5,272.00
115.00
1,730.00
-
Consolidated Net Income
34,504.00
9,400.00
51,802.00
60,058.00
89,490.00
130,999
Net Income
34,504.00
9,400.00
51,802.00
60,058.00
89,490.00
130,999
Net Income After Extraordinaries
34,504.00
9,400.00
51,802.00
60,058.00
89,490.00
130,999
Net Income Available to Common
33,068.00
8,968.00
51,802.00
60,058.00
89,490.00
130,999
EPS (Basic)
1.96
0.53
2.86
2.77
3.97
4.87
Basic Shares Outstanding
16,873.00
14,837.00
18,111.00
21,711.00
22,558.00
26,886
EPS (Diluted)
2.10
0.53
2.86
2.77
3.97
4.87
Diluted Shares Outstanding
16,873.00
17,107.00
18,111.00
21,711.00
22,558.00
26,886
EBITDA
57,084.00
18,669.00
57,002.00
62,576.00
86,765.00
113,563
Other After Tax Income (Expense)
16,417.00
823.00
-
-
-
-
Preferred Dividends
1,436.00
432.00
-
-
-
-

About Adamas Pharmaceuticals

View Profile
Address
1900 Powell Street
Emeryville California 94608
United States
Employees -
Website http://www.adamaspharma.com
Updated 07/08/2019
Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products includes ADS-5012, ADS-4101, and Namenda XR. The ADS-5102 is a treatment for levodopa-induced dyskinesia in patients with Parkinson's disease.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.